A little more than six months ago (June 21, 2021), the United States District Court for the District of New Jersey began enforcing its Local Rule 7.1.1, requiring disclosure of third-party litigation funding. Local Rule 7.1.1 provides:
Within 30 days of filing an initial pleading or transfer of the matter to this district, including the
We have promised ourselves that we will stream this week’s “This Is Us” episode when we finish this blog post. We love this series beyond reason, and we dread its imminent demise, notwithstanding the title’s grammatical transgression. (We generally condition any sort of allegiance on correct use of predicate nominatives.) We are struck, over and
In general, people do not like to have to repeat themselves. It is unavoidable. Sometimes your audience is rightfully (or wrongfully) distracted. Sometimes you aren’t that clear. Sometimes you lose your zoom audio connection and have to start over. Sometimes you don’t notice your daughter’s earbuds are in and that she’s been watching a YouTube
In the movie Thank You for Smoking, lobbyists for the tobacco, alcohol, and firearm industries got together periodically at a DC watering hole to swap stories about the challenges of representing unpopular clients under increasing scrutiny by the federal government. Hilarity ensued, along with some other stuff we do not remember very well. Of course,
This post is from the non-Reed Smith side of the blog.
Shouldn’t you call it a duck? Apparently not in New Jersey. Primarily because New Jersey is still governed by one of our Bottom Ten decisions of 2012 — Cornett v. Johnson & Johnson, 48 A.3d 1041 (N.J. 2012). Today’s ducky decision was handed
One of the intriguing things about cases decided by a jurisdiction’s highest court is that pronouncements by such courts can often have far-reaching implications. Sometimes they pan out, as the application of the First Amendment to the FDA’s ban on off-label promotion seems to be doing following Sorrell v. IMS Health, Inc., 564 U.S.
We have been consistently critical of the MDL system for encouraging judges presiding over such massive aggregations to manipulate the applicable law to create settlement pressure on defendants. We’ve seen that with federal preemption, willingness to create novel state-law causes of action, choice of law, and trial consolidation of multiple plaintiffs.
We are six weeks into 2021 and for most, it stills feels a lot like 2020. We are starting to hear about restrictions being lifted or modified to allow for more . . . well more anything. But that’s happening just as almost the entire country is being overwhelmed by a polar vortex. Ice, snow,
We refuse to end the year on a bad note, so we’ll talk about a case that’s good – not good enough to make tomorrow’s top-ten list, but good enough to slam the door shut on 2020 with a reasonable amount of cheer.
Vicente v. Johnson & Johnson, 2020 WL 7586907 (D.N.J. Dec. 21,
We haven’t see too many of these. The reason for that is the gadolinium litigation is practically a textbook example of where federal law ought to preempt state-law product liability claims of all kinds—including both design defect claims and failure-to-warn claims. Just search gadolinium on the blog and you’ll find plenty of cases dismissed on